Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 2/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30251163 | 1.00 | GRM5 (0.38) | GRM5VNN1ADRA1DADRA1ATNF | |
| SCHEMBL30251244 | 1.00 | GRM5 (0.38) | GRM5VNN1ADRA1DADRA1ATNF | |
| SCHEMBL30251162 | 1.00 | GRM5 (0.38) | GRM5VNN1ADRA1DADRA1ATNF | |
| SCHEMBL23882920 | 1.00 | GRM5 (0.38) | GRM5VNN1ADRA1DADRA1ATNF | |
| SCHEMBL26159492 | 1.00 | GRM5 (0.38) | GRM5VNN1ADRA1DADRA1ATNF | |
| SCHEMBL23882869 | 0.90 | GRM5 (0.39) | GRM5VNN1ADRA1DADRA1ATNF | |
| SCHEMBL23905970 | 0.90 | GRM5 (0.39) | GRM5VNN1ADRA1DADRA1ATNF | |
| SCHEMBL30251017 | 0.90 | GRM5 (0.39) | GRM5VNN1ADRA1DADRA1ATNF | |
| SCHEMBL26159421 | 0.90 | GRM5 (0.39) | GRM5VNN1ADRA1DADRA1ATNF | |
| SCHEMBL23906321 | 0.90 | GRM5 (0.39) | GRM5ADRA1DADRA1ATNFADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| WO-2021198283-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | HLA-DRB1, CD74, HLA-C | GRM5 2303/4885VNN1 2710/4885ADRA1D 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.